biotech

The Five Best-Performing Biotech Stocks of 2011 -- So Far

Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and -- perhaps most important -- are in far less danger from generic competition. Here are the big winners so far.

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:

Why Samsung Electronics Should Say No to Drugs

Samsung Electronics is known for its smartphones, TVs and memory chips. Now it wants to tackle biopharmaceuticals, on Friday announcing a new joint venture to produce drugs to treat cancer and arthritis.

Two Reasons for Clinical Data Shares to Soar Again

From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.

What Pfizer Sees in Lpath's Innovative Blindness Drugs

Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention -- and lots of money -- from Pfizer. More of both could be coming.

Six Stocks to Buy for Real Revenue Growth in 2011

The path to profits for most of Corporate America lately has been cutting costs rather than raising revenue. But a careful look reveals a few companies that are poised to deliver real revenue growth. We've found six with a plus: Their stocks look like bargains.

What a Wild Year It Was
for Health Care

Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our list of the year's biggest health stories.

Genzyme Talks Up Possible Sales of Its New MS Drug

Biotechnology company Genzyme is holding an analyst and investor meeting Monday focused on the commercial potential of its multiple sclerosis drug Campath as it tries to convince Sanofi-Aventis that it's worth more than the Paris-based pharmaceutical giant has been offering.

Tiny Spectrum Pharmaceuticals Is Getting Plenty of Attention

What's Spectrum's particular allure? Beyond being the subject of takeover rumor, it has two oncology drugs approved by the Food and Drug Administration that are already on the market, plus two other promising drugs that are in late-stage clinical trials.

Is ImmunoCellular Another Rising Star in Biotech?

Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCellular is still pretty much an unknown.